Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas